-
公开(公告)号：US08916691B2
公开(公告)日：2014-12-23
申请号：US11545349
申请日：2006-10-10
IPC分类号： C07K1/36 , C07K1/22 , C07K14/435 , C07K16/18 , C07K14/78 , A61L27/38 , C07K14/47 , A61K48/00 , A61K35/12 , A61K35/00
CPC分类号： A61L27/3856 , A61K35/12 , A61K35/13 , A61K48/00 , A61K2121/00 , C07K14/47 , C07K14/78 , C07K16/18 , C12N2799/022
摘要： Methods of expressing LIM mineralization protein in mammalian cells are described. Methods of expressing LIM mineralization protein and assessing glycosylation of the LIM mineralization protein in prokaryotic and non-mammalian eukaryotic cells are also described. The methods involve transfecting the cells with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein. Transfection may be accomplished in vitro, ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid.
摘要翻译： 描述了在哺乳动物细胞中表达LIM矿化蛋白的方法。 还描述了在原核和非哺乳动物真核细胞中表达LIM矿化蛋白和评估LIM矿化蛋白的糖基化的方法。 所述方法包括用包含编码LIM矿化蛋白的核苷酸序列的分离的核酸转染细胞。 转染可以通过直接注射病毒或裸露DNA或非病毒载体如质粒在体外，离体或体内完成。
-
2.发明申请Novel bone mineralization protein expression systems, and methods of studying their intracellular signaling pathways 有权新型骨矿化蛋白表达系统及其细胞内信号通路的研究方法公开(公告)号：US20080254001A9
公开(公告)日：2008-10-16
申请号：US11546891
申请日：2006-10-12
CPC分类号： G01N33/5044 , A61K48/005 , C07K14/52 , C12N5/0654 , C12N2501/998 , C12N2503/00 , C12N2510/00 , C12N2799/022 , C12N2799/06 , G01N33/5041 , G01N33/5061 , G01N33/6887 , G01N33/74
摘要： The present invention is directed to methods of switching a differentiation of a cell from a non-osteogenic lineage into an osteogenic lineage. The present invention is also directed to methods of generating a model system for assessing the intracellular signaling pathways of bone growth factors.
摘要翻译： 本发明涉及将细胞从非成骨谱系分化成成骨谱系的方法。 本发明还涉及产生用于评估骨生长因子的细胞内信号传导途径的模型系统的方法。
-
公开(公告)号：US20080089866A1
公开(公告)日：2008-04-17
申请号：US11546891
申请日：2006-10-12
CPC分类号： G01N33/5044 , A61K48/005 , C07K14/52 , C12N5/0654 , C12N2501/998 , C12N2503/00 , C12N2510/00 , C12N2799/022 , C12N2799/06 , G01N33/5041 , G01N33/5061 , G01N33/6887 , G01N33/74
摘要： The present invention is directed to methods of switching a differentiation of a cell from a non-osteogenic lineage into an osteogenic lineage. The present invention is also directed to methods of generating a model system for assessing the intracellular signaling pathways of bone growth factors.
-
4.发明授权Bone mineralization protein expression systems, and methods of studying intracellular signaling pathways induced thereby 有权骨矿化蛋白表达系统，以及研究由此诱导的细胞内信号通路的方法公开(公告)号：US07741117B2
公开(公告)日：2010-06-22
申请号：US11546891
申请日：2006-10-12
CPC分类号： G01N33/5044 , A61K48/005 , C07K14/52 , C12N5/0654 , C12N2501/998 , C12N2503/00 , C12N2510/00 , C12N2799/022 , C12N2799/06 , G01N33/5041 , G01N33/5061 , G01N33/6887 , G01N33/74
摘要： The present invention is directed to methods of switching a differentiation of a cell from a non-osteogenic lineage into an osteogenic lineage. The present invention is also directed to methods of generating a model system for assessing the intracellular signaling pathways of bone growth factors.
摘要翻译： 本发明涉及将细胞从非成骨谱系分化成成骨谱系的方法。 本发明还涉及产生用于评估骨生长因子的细胞内信号传导途径的模型系统的方法。
-
5.发明申请NOGGIN INHIBITORY COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO 有权用于操作的NOGGIN抑制组合物及其相关方法公开(公告)号：US20130337082A1
公开(公告)日：2013-12-19
申请号：US13980598
申请日：2012-02-23
CPC分类号： A61L27/00 , A61L27/12 , A61L27/227 , A61L27/54 , A61L2300/414 , A61L2300/432 , A61L2430/02
摘要： This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement in combination with a Noggin blocker.
摘要翻译： 本公开涉及用于形成骨的化合物和组合物及其相关方法。 在某些实施方案中，本公开内容涉及形成骨的方法，包括在Noggin阻断剂组合的期望骨生长或增强的部位，在受试者中植入包含生长因子如BMP的骨移植组合物。
-
公开(公告)号：US11179500B2
公开(公告)日：2021-11-23
申请号：US13980593
申请日：2012-02-23
摘要： This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement in combination with a JAB1 blocker.
-
公开(公告)号：US20100119538A9
公开(公告)日：2010-05-13
申请号：US11602120
申请日：2006-11-20
IPC分类号： A61K39/21 , C07H21/04 , C12N15/867 , C07H21/02 , C07K14/16
CPC分类号： C07K16/18 , A61K35/12 , A61K35/13 , A61K48/00 , A61K2121/00 , A61L27/3843 , A61L27/3856 , A61L27/3895 , C07K14/47 , C07K14/78 , C12N2799/022
摘要： Compositions comprising osteogenic factors fused with membrane transduction domains of viral proteins are provided. Also provided are methods of expression and use of such compositions. Further, the methods of making such compositions are also provided. The methods involve transfecting the cells with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter and optionally a membrane transduction domain of a viral protein. Transfection may be accomplished ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid. Methods for treating disc disease associated with trauma or disc degeneration are also described.
-
8.发明授权公开(公告)号：US09295754B2
公开(公告)日：2016-03-29
申请号：US13980598
申请日：2012-02-23
CPC分类号： A61L27/00 , A61L27/12 , A61L27/227 , A61L27/54 , A61L2300/414 , A61L2300/432 , A61L2430/02
摘要： This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement in combination with a Noggin blocker.
摘要翻译： 本公开涉及用于形成骨的化合物和组合物及其相关方法。 在某些实施方案中，本公开内容涉及形成骨的方法，包括在Noggin阻断剂组合的期望骨生长或增强的部位，在受试者中植入包含生长因子如BMP的骨移植组合物。
-
9.发明申请Methods and kits using a molecular interaction between a Smurf-1 WW domain and LIM mineralization protein isoforms 有权使用Smurf-1 WW结构域和LIM矿化蛋白质亚型之间的分子相互作用的方法和试剂盒公开(公告)号：US20070190572A1
公开(公告)日：2007-08-16
申请号：US11607348
申请日：2006-12-01
CPC分类号： G01N33/6893 , A61K38/1709 , A61K38/1875 , G01N2333/51 , G01N2500/00 , G01N2800/10 , A61K2300/00
摘要： The instant application provides kits and methods for identifying agents which induce or inhibit the osteogenic effect of LMP or BMP proteins. The kits are directed to methods which measure either an amount of a complex between a Smurf protein or a fragment thereof and an LMP protein or a fragment thereof. Alternatively, the kits are directed to methods of measuring an amount of the ubiquitinated Smad protein or a fragment thereof.
摘要翻译： 本申请提供用于鉴定诱导或抑制LMP或BMP蛋白的成骨作用的试剂的试剂盒和方法。 试剂盒涉及测量Smurf蛋白质或其片段与LMP蛋白质或其片段之间的复合物的量的方法。 或者，试剂盒涉及测量泛素化的Smad蛋白或其片段的量的方法。
-
10.发明申请BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO 审中-公开骨形成蛋白途径激活，用于OSSIFICATION的组合物及其相关方法公开(公告)号：US20140248372A1
公开(公告)日：2014-09-04
申请号：US14345661
申请日：2012-09-17
IPC分类号： A61K31/436 , A61K33/42 , A61K38/18
CPC分类号： A61L27/54 , A61K31/05 , A61K31/07 , A61K31/136 , A61K31/196 , A61K31/203 , A61K31/232 , A61K31/404 , A61K31/407 , A61K31/4174 , A61K31/4184 , A61K31/436 , A61K31/4745 , A61K31/475 , A61K31/506 , A61K31/5377 , A61K31/56 , A61K31/585 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K33/42 , A61K38/1875 , A61K38/39 , A61L27/12 , A61L27/24 , A61L27/46 , A61L27/52 , A61L2300/414 , A61L2300/45 , A61L2430/02 , C08L89/06 , A61K2300/00
摘要： The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
摘要翻译： 本公开涉及用于骨形成，骨折治疗，骨移植，骨融合，软骨维持和修复的化合物和组合物及其相关方法。 在某些实施方案中，本公开涉及包含一种或多种本文公开的化合物的组合物，例如克霉唑，厚朴酚，厚朴酚，他克莫司，吡美莫司，西罗莫司，依维莫司，替西罗莫司，螺内酯，氟替卡松，丙酸氟替卡松，糠酸氟替卡松，利奈唑胺， 替米沙坦，维A酸，视黄醇，异维A酸，维A酸，维A酸，视黄酸（维甲酸），替尼泊苷，丝裂霉素C，阿糖胞苷，地西他滨，长春新碱，长春新碱，长春新碱，长春瑞滨，心灵素，多柔比星，柔红霉素，表柔比星，伊达比星，米托蒽醌， ，拓扑替他啶，托泊替康，喜树碱，伊立替康，舒尼替尼，其衍生物或其盐，用于骨生长过程。 在典型的实施方案中，将骨移植组合物植入受试者在所需骨生长或增强部位。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.027 秒)
